Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 493 clinical trials
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

doxorubicin
rituximab
cell transplantation
b-cell lymphoma
gemcitabine
  • 13 views
  • 15 Feb, 2022
  • 1 location
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

cell transplantation
gemcitabine
salvage therapy
rituximab
b-cell lymphoma
  • 0 views
  • 15 Feb, 2022
  • 1 location
Thalidomide Maintenance Treatment in DLBCL

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

b-cell lymphoma
rituximab
  • 16 views
  • 21 Jan, 2021
  • 1 location
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in relapsed or refractory DLBCL.

  • 0 views
  • 11 May, 2022
  • 1 location
A Single-arm, Multi-center, Phase Ib/II Study of Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients (Xplore Trial)

, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated EBV-positive diffuse large B-cell lymphoma (DLBCL) patients.

  • 0 views
  • 28 Oct, 2022
R-MTX-zanbrutinib in Secondary CNS Lymphoma

Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of retrospective

  • 0 views
  • 17 Jun, 2022
  • 1 location
CD19/79b Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi-specific CAR-T cells and …

  • 0 views
  • 07 Jul, 2022
  • 1 location
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

  • 0 views
  • 23 Apr, 2022
  • 1 location
CD19/22 Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and …

  • 0 views
  • 07 Jul, 2022
  • 1 location
New Clinical End-points in Patients With Primary Sjögren's Syndrome (NECESSITY)

There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing Response to treatment (STAR) will allow a more specific …

  • 4 views
  • 14 May, 2022
  • 1 location